Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 462

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Open access
Magbanua, M.J.M., Swigart, L.B., Wu, H.-T., Hirst, G.L., Yau, C., Wolf, D.M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., Delson, A.L., DeMichele, A., Liu, M.C., Chien, A.J., Tripathy, D., Asare, S., Lin, C.-H.J., Billings, P., Aleshin, A., Sethi, H., Louie, M., Zimmermann, B., Esserman, L.J., van ‘t Veer, L.J.·2021·Annals of Oncology

Abstract

BACKGROUND: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence. PATIENTS AND METHODS: Cell-free DNA (cfDNA) was isolated from 291 plasma samples of 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL with standard NAC alone or combined with MK-2206 (AKT inhibitor) treatment. Blood was collected at pretreatment (T0), 3 weeks after initiation of paclitaxel (T1), between paclitaxel and anthracycline regimens (T2), or prior to surgery (T3). A personalized ctDNA test was designed to detect up to 16 patient-specific mutations (from whole-exome sequencing of pretreatment tumor) in cfDNA by ultra-deep sequencing. The median follow-up time for survival analysis was 4.8 years. RESULTS: At T0, 61 of 84 (73%) patients were ctDNA positive, which decreased over time (T1: 35%; T2: 14%; and T3: 9%). Patients who remained ctDNA positive at T1 were significantly more likely to have residual disease after NAC (83% non-pCR) compared with those who cleared ctDNA (52% non-pCR; odds ratio 4.33, P = 0.012). After NAC, all patients who achieved pCR were ctDNA negative (n = 17, 100%). For those who did not achieve pCR (n = 43), ctDNA-positive patients (14%) had a significantly increased risk of metastatic recurrence [hazard ratio (HR) 10.4; 95% confidence interval (CI) 2.3-46.6]; interestingly, patients who did not achieve pCR but were ctDNA negative (86%) had excellent outcome, similar to those who achieved pCR (HR 1.4; 95% CI 0.15-13.5). CONCLUSIONS: Lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival even in patients who did not achieve pCR. Personalized monitoring of ctDNA during NAC of high-risk early breast cancer may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.11.007

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 462

Metadata

Authors
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., Delson, A. L., DeMichele, A., Liu, M. C., Chien, A. J., Tripathy, D., Asare, S., Lin, C.-H. J., Billings, P., Aleshin, A., Sethi, H., Louie, M., Zimmermann, B., Esserman, L. J., & van ‘t Veer, L. J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-02
Volume
32
Issue
2
Pages
229-239
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3109124091
Cited by
462
References
47
FWCI
14.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. https://app.cochat.ai/papers/10.1016/j.annonc.2020.11.007
The paper
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., Delson, A. L., DeMichele, A., Liu, M. C., Chien, A. J., Tripathy, D., Asare, S., Lin, C.-H. J., Billings, P., Aleshin, A., . . . van ‘t Veer, L. J. (2021). Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.11.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.